Strategic Education, Inc. Reports Fourth Quarter 2023 Results
HERNDON, Va.–(BUSINESS WIRE)–Strategic Education, Inc. (Strategic Education) (NASDAQ: STRA) today announced financial results for the period ended December... Read more.
Bakkt Announces Preliminary 2023 Financial Results; Preliminary Estimates Within Previously Provided Guidance
ALPHARETTA, Ga.–(BUSINESS WIRE)–Bakkt Holdings, Inc. (“Bakkt”) (NYSE: BKKT) announced certain preliminary financial results for the fourth quarter... Read more.
World Cell Based Assay & High Content Screening Markets 2024-2028 with Executive and Consultant Guides – Immuno-oncology, Biotechnology and Pharmaceutical Research Play Leading Roles – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cell Based Assay & High Content Screening Markets. Forecasts by User and Product. With Executive and Consultant... Read more.
Emerald Reports Fourth Quarter and Full Year 2023 Financial Results
Revenue Growth of 17.5% Year-over-Year NEW YORK–(BUSINESS WIRE)–Emerald Holding, Inc. (NYSE: EEX) (“Emerald” or the “Company”), America’s largest... Read more.
GoodRx Reports Fourth Quarter and Full Year 2023 Results
SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription... Read more.
FREYR Battery Reports Fourth Quarter and Full Year 2023 Results
NEW YORK & OSLO, Norway & NEWNAN, Ga.–(BUSINESS WIRE)–FREYR Battery, Inc. (NYSE: FREY) (“FREYR” or the “Company”), a developer of clean,... Read more.
ACI Worldwide, Inc. Reports Financial Results for the Quarter and Full Year Ended December 31, 2023
Q4 2023 HIGHLIGHTS Total revenue of $477 million grew 5%1 Total recurring revenue grew 7%1 Net income of $123 million grew 36% Total EBITDA of $210 million grew... Read more.
OM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024
Dr. Carl Marci to present on utilizing real-world data for multiple sclerosis research to improve understanding and treatment of the disease –(BUSINESS WIRE)–OM1:... Read more.
MultiPlan Reports Fourth Quarter and Full Year 2023 Results
– Q4 2023 Revenues of $244.1 million, Net Loss of $31.4 million and Adjusted EBITDA of $156.8 million – Full Year 2023 Revenues of $961.5 million, Net Loss of... Read more.
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases
PARIS–(BUSINESS WIRE)–Genethon, a non-profit research organization focused on developing gene therapies for rare diseases, today marks International... Read more.